Across TCGA pan-cancer cohorts, DEFB129 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated DEFB129 data layer compared with 6 for mass-spec protein and 1 for mass-spec protein.
The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher DEFB129 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated DEFB129 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.
SKCM are the cancer types where DEFB129 Mutation most reproducibly stratifies survival.